CODEN [USA]: IAJPBB ISSN : 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES
SJIF Impact Factor: 7.187
https://doi.org/10.5281/zenodo.21360805

Available online at: http://www.iajps.com Research Article

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR ESTIMATION OF PAZOPANIB IN BULK FORM AND PHARMACEUTICAL TABLET DOSAGE FORM

Dr. T.Mahender*[1], Munazzah[2], MD Wakkas Ali[2], Pratyush Kumar Garada[2], N Shiva Shankar[2]

1- Associate Professor, Department of Pharmaceutical Chemistry, Avanthi Institute of Pharmaceutical Sciences, Hayathnagar, Gunthapally, Hyderabad, Telangana-501512

2-Students, Department of Pharmaceutical Analysis, Avanthi Institute of Pharmaceutical Sciences, Hayathnagar, Gunthapally, Hyderabad, Telangana-501512

Abstract:

A new, simple, rapid, precise, accurate and reproducible RP-HPLC method for estimation of Pazopanib in bulk form and marketed pharmaceutical dosage forms. Separation of Pazopanib was successfully achieved on a Symmetry ODS C18 (4.6 x 250mm, 5µm) column in an isocratic mode of separation utilizing Acetonitrile: Methanol in the ratio of 80:20% v/v at a flow rate of 1.0 mL/min and the detection was carried out at 272nm. The method was validated according to ICH guidelines for linearity, sensitivity, accuracy, precision, specificity and robustness. The response was found to be linear in the drug concentration range of 10-50mcg/mL for Pazopanib. The correlation coefficient was found to be 0.999 for Pazopanib. The LOD and LOQ for Pazopanib were found to be 1.1µg/mL and 3.2µg/mL respectively. The proposed method was found to be good percentage recovery for Pazopanib, which indicates that the proposed method is highly accurate. The specificity of the method shows good correlation between retention times of standard solution with the sample solution. Therefore, the proposed method specifically determines the analyte in the sample without interference from excipients of pharmaceutical dosage forms.

Keywords: *Pazopanib, RP-HPLC, Accuracy, ICH Guidelines.*

Corresponding author:

Dr. T.Mahender,
Associate Professor,
Department of Pharmaceutical Chemistry,
Avanthi Institute of Pharmaceutical Sciences,
Hayathnagar, Gunthapally,
Hyderabad, Telangana-501512

QR CODE

Please cite this article in press T.Mahender et al., ***Development And Validation Of Rp-Hplc Method For Estimation Of Pazopanib In Bulk Form And Pharmaceutical Tablet Dosage Form****, Indo Am. J. P. Sci, 2026; 13(07).*

INTRODUCTION:

Pazopanib is a pyrimidine that is 5-(pyrimidin-2-yl} amino-2-methylbenzenesulfonamide substituted at position 4 by a (2, 3-dimethylindazol-6-yl) (methyl) amino group. Used as its hydrochloride salt for treatment of kidney cancer[1]. It has a role as an antineoplastic agent, a tyrosine kinase inhibitor, a vascular endothelial growth factor receptor antagonist and an angiogenesis modulating agent. It is a member of indazoles, an amino pyrimidine and a sulfonamide. It is a conjugate base of a Pazopanib (1+). Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity[2]. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. Pazopanib is a second-generation multitargeted tyrosine kinase inhibitor against vascular endothelial growth factor receptor-1, -2, and -3, platelet-derived growth factor receptor-alpha, platelet-derived growth factor receptor-beta, and c-kit. These receptor targets are part of the angiogenesis pathway that facilitates the formation of tumour blood vessel for tumour survival and growth. Pazopanib is a cancer medicine that is used to treat patients with kidney cancer (advanced renal cell carcinoma)[3]. It is also used to treat advanced soft tissue sarcoma (STS) in patients who have received other cancer treatments. The IUPAC Name of 5-[[4-[(2, 3-dimethyl indazol-6-yl)-methyl amino] pyrimidin-2-yl] amino]-2-methyl benzene sulfonamide. The Chemical Structure of Pazopanib is shown in figure-1.



Fig-1: Chemical Structure of Pazopanib

EXPERIMENTAL METHODS

Table-1: Instruments Used

S.No.	Instruments and Glass wares	Model
1	HPLC	WATERS Alliance 2695 separation module, Software: Empower 2, 996 PDA Detector.
2	pH meter	Labindia
3	Weighing machine	Sartorius
4	Volumetric flasks	Borosil
5	Pipettes and Burettes	Borosil
6	Beakers	Borosil
7	Digital ultra sonicator	Labman

Table-2: Chemicals Used

S.No.	Chemical	Brand Names
1	Pazopanib (Pure)	Synpharma Research Lab, Hyderabad
2	Water and Methanol for HPLC	LICHROSOLV (MERCK)
3	Acetonitrile for HPLC	Merck

HPLC METHOD DEVELOPMENT:

Preparation of Standard Solution:

Accurately weigh and transfer 10 mg of Pazopanib working standard into a 10ml of clean dry volumetric flasks add about 7ml of Methanol and sonicate to dissolve and removal of air completely and make volume up to the mark with the same Methanol.

Further pipette 0.3ml of the above Pazopanib stock solutions into a 10ml volumetric flask and dilute up to the mark with Methanol.

Preparation of Sample Solution:

Take average weight of the Powder and weight 10 mg equivalent weight of Pazopanib sample into a 10mL clean dry volumetric flask and add about 7mL of Diluent and sonicate to dissolve it completely and make volume up to the mark with the same solvent.

Further pipette 0.3ml of the above Pazopanib stock solutions into a 10ml volumetric flask and dilute up to the mark with Methanol.

Procedure:

Inject the samples by changing the chromatographic conditions and record the chromatograms, note the conditions of proper peak elution for performing validation parameters as per ICH guidelines[32-33].

Mobile Phase Optimization:

Initially the mobile phase tried was methanol: Water and ACN: Water with varying proportions. Finally, the mobile phase[4] was optimized to ACN: Methanol 80:20% v/v) respectively.

Optimization of Column:

The method was performed with various C_{18} columns like Symmetry, Zodiac and Xterra. Symmetry ODS C18 (4.6 x 250mm, 5µm) Column was found to be ideal as it gave good peak shape and resolution[5] at 1ml/min flow.

Preparation of Mobile Phase:

Accurately measured 800 ml (80%) of HPLC Acetonitrile and 200 ml of Methanol (20%) were mixed and degassed in a digital ultra sonicater for 15 minutes and then filtered through 0.45 µ filter under vacuum filtration.

Diluent Preparation:

The Mobile phase was used as the diluent.

METHOD VALIDATION

Validation Parameters

System Suitability

Accurately weigh and transfer 10 mg of Pazopanib working standard into a 10ml of clean dry volumetric flasks add about 7mL of Diluents and sonicate to dissolve it completely and make volume up to the mark with the same solvent. (Stock solution)

Further pipette 0.3ml of the above Pazopanib stock solutions into a 10ml volumetric flask and dilute up to the mark with Methanol.

Procedure:

The standard solution was injected for five times and measured the area for all five injections in HPLC. The %RSD for the area of five replicate injections was found to be within the specified limits.

Specificity:

Preparation of Standard Solution:

Accurately weigh and transfer 10 mg of Pazopanib working standard into a 10ml of clean dry volumetric flasks add about 7ml of Diluents and sonicate to dissolve it completely and make volume up to the mark with the same solvent. (Stock solution)

Further pipette 0.3ml of the above Pazopanib stock solutions into a 10ml volumetric flask and dilute up to the mark with Methanol.

Preparation of Sample Solution:

Take average weight of the Powder and weight 10 mg equivalent weight of Pazopanib sample into a 10mL clean dry volumetric flask and add about 7mL of Diluent and sonicate to dissolve it completely and make volume up to the mark with the same solvent.

Further pipette 0.3ml of the above Pazopanib stock solutions into a 10ml volumetric flask and dilute up to the mark with Methanol.

Procedure:

Inject the five replicate injections of standard and inject the three replicate injections sample solutions and calculate the assay[6] by using formula:

$$\%ASSAY = \frac{\text{Sample area}}{\text{Standard area}} \times \frac{\text{Weight of standard}}{\text{Dilution of standard}} \times \frac{\text{Dilution of sample}}{\text{Weight of sample}} \times \frac{\text{Purity}}{100} \times \frac{\text{Weight of tablet}}{\text{Label claim}} \times 100$$

Linearity:

Accurately weigh and transfer 10 mg of Pazopanib working standard into a 10ml of clean dry volumetric flasks add about 7ml of Diluents[7] and sonicate to dissolve it completely and make volume up to the mark with the same solvent. (Stock solution)

Preparation of Level – I (10ppm of Pazopanib):

Take 0.1ml of stock solution in to 10ml of volumetric flask and make up the volume up to mark with diluent.

Preparation of Level – II (20ppm of Pazopanib):

Take 0.2ml of stock solution in to 10ml of volumetric flask and make up the volume up to mark with diluent.

Preparation of Level – III (30ppm of Pazopanib):

Take 0.3ml of stock solution in to 10ml of volumetric flask and make up the volume up to mark with diluent.

Preparation of Level – IV (40ppm of Pazopanib):

Take 0.4ml of stock solution in to 10ml of volumetric flask and make up the volume up to mark with diluent.

Preparation of Level – V (50ppm of Pazopanib):

Take 0.5ml of stock solution in to 10ml of volumetric flask and make up the volume up to mark with diluent.

Procedure:

Inject each level into the chromatographic system[8] and measure the peak area.

Plot a graph of peak area versus concentration (on X-axis concentration and on Y-axis Peak area) and calculate the correlation coefficient.

Precision

Repeatability

Preparation of Pazopanib Product Solution for Precision:

Accurately weigh and transfer 10 mg of Pazopanib working standard into a 10ml of clean dry volumetric flasks add about 7ml of Diluents and sonicate to dissolve it completely and make volume up to the mark with the same solvent. (Stock solution)

Take 0.3ml of stock solution in to 10ml of volumetric flask and make up the volume up to mark with diluent.

The standard solution was injected for six times and measured the area for all six injections in HPLC. The %RSD for the area of six replicate injections was found to be within the specified limits.

Intermediate Precision:

To evaluate the intermediate precision[9] (also known as Ruggedness[10]) of the method, Precision was performed on different days by maintaining same conditions.

Procedure:

Analyst 1:

The standard solution was injected for six times and measured the area for all six injections in HPLC. The %RSD for the area of six replicate injections was found to be within the specified limits.

Analyst 2:

The standard solution was injected for six times and measured the area for all six injections in HPLC. The %RSD for the area of six replicate injections was found to be within the specified limits.

Accuracy:

For Preparation of 50% Standard Stock Solution:

Accurately weigh and transfer 10 mg of Pazopanib working standard into a 10ml of clean dry volumetric flasks add about 7mL of Diluents and sonicate to dissolve it completely and make volume up to the mark with the same solvent. (Stock solution)

Take 0.15ml of stock solution in to 10ml of volumetric flask and make up the volume up to mark with diluent.

For Preparation of 100% Standard Stock Solution:

Accurately weigh and transfer 10 mg of Pazopanib working standard into a 10ml of clean dry volumetric flasks add about 7mL of Diluents and sonicate to dissolve it completely and make volume up to the mark with the same solvent. (Stock solution)

Take 0.3ml of stock solution in to 10ml of volumetric flask and make up the volume up to mark with diluent.

For Preparation of 150% Standard Stock Solution:

Accurately weigh and transfer 10 mg of Pazopanib working standard into a 10ml of clean dry volumetric flasks add about 7mL of Diluents and sonicate to dissolve it completely and make volume up to the mark with the same solvent. (Stock solution)

Take 0.45ml of stock solution in to 10ml of volumetric flask and make up the volume up to mark with diluent.

Procedure:

Inject the Three replicate injections of individual concentrations (50%, 100%, 150%) were made under the optimized conditions[11]. Recorded the chromatograms and measured the peak responses. Calculate the Amount found and Amount added for Pazopanib and calculate the individual recovery[12] and mean recovery values.

Limit of Detection (LOD) and Limit of Quantification (LOQ):

Preparation of 0.597µg/ml solution (LOD):

Accurately weigh and transfer 10 mg of Pazopanib working standard into a 10ml of clean dry volumetric flasks add about 7ml of Methanol and sonicate to dissolve and removal of air completely and make volume up to the mark with the same Methanol.

Further pipette 0.00597ml of the above Pazopanib stock solutions into a 10ml volumetric flask and dilute up to the mark with Methanol.

Preparation of 1.811µg/ml solution (LOQ):

Accurately weigh and transfer 10 mg of Pazopanib working standard into a 10ml of clean dry volumetric flasks add about 7ml of Methanol and sonicate to dissolve and removal of air completely and make volume up to the mark with the same Methanol.

Further pipette 0.01811ml of the above Pazopanib stock solutions into a 10ml volumetric flask and dilute up to the mark with Methanol.

Robustness:

The analysis was performed in different conditions to find the variability of test results. The following conditions are checked for variation of results. .

For preparation of Standard Solution:

Accurately weigh and transfer 10 mg of Pazopanib working standard into a 10ml of clean dry volumetric flasks add about 7mL of Diluents and sonicate to dissolve it completely and make volume

up to the mark with the same solvent. (Stock solution)

Take 0.3ml of stock solution in to 10ml of volumetric flask and make up the volume up to mark with diluent.

Effect of Variation of Flow Conditions:

The sample was analyzed at 0.9ml/min and 1.1ml/min instead of 1ml/min, remaining conditions are same. 20µl of the above sample was injected and chromatograms were recorded.

Effect of Variation of Mobile Phase Organic Composition:

The sample was analyzed by variation of mobile phase i.e. ACN: Methanol was taken in the ratio and 75:25, 85:15 instead of 80:20, remaining conditions are same. 20µl of the above sample was injected and chromatograms were recorded.

RESULTS AND DISCUSSION:

Development of Analytical Method:

Several concurrent trails developed the proposed method to establish the preferred chromatographic conditions, which would be helpful to conduct a complete validation study[13]. The mobile phase for consisting of Acetonitrile and methanol (80:20% v/v) at 1-mL/min flow rate and detection wavelength 272 nm was optimized, which gave sharp peak, minimum tailing factor with short run time for Pazopanib. The retention time[14] for Pravastatin was found to be 3.167 minutes (Figure 2).

Optimized Chromatographic Condition

Column	:	Symmetry ODS C18 (4.6 x 250mm, 5µm)
Column temperature	:	Ambient
Wavelength	:	272 nm
Mobile phase ratio	:	ACN: Methanol (80:20% v/v)
Flow rate	:	1.0mL/min
Injection volume	:	20 µl
Run time	:	8 minutes



Fig-2: Optimized Chromatographic Condition of Pazopanib

Validation of Analytical Method

Validation of the developed HPLC method[15] was carried out according to the International Council on Harmonization (ICH) guidelines Q2 (R1) for linearity and range, accuracy, precision, LOD and LOQ, specificity and robustness by the following procedure.

System Suitability

Standard solutions were prepared as per the test method and injected into the chromatographic system. The system suitability parameters[16] like theoretical plates, resolution and asymmetric factor were evaluated. The results were presented in Table 3.

Table-3: Results of System Suitability for Pazopanib

S.No.	Peak Name	RT	Area (µV*sec)	Height (µV)	USP Plate Count	USP Tailing
1	Pazopanib	3.192	225645	20584	6286	1.38
2	Pazopanib	3.146	225847	20965	6358	1.39
3	Pazopanib	3.123	228656	20758	6285	1.41
4	Pazopanib	3.167	228547	20859	6278	1.40
5	Pazopanib	3.158	229658	20968	6395	1.42

Mean			227670.6			
Std. Dev.			1810.899			
% RSD			0.795403			

Specificity

The specificity[17] was studied to examine the presence of interfering components, while in the comparison of Chromatograms; there was no interference from blank and standard Chromatogram.

$$\%ASSAY = \frac{\text{Sample area}}{\text{Standard area}} \times \frac{\text{Weight of standard}}{\text{Dilution of standard}} \times \frac{\text{Dilution of sample}}{\text{Weight of sample}} \times \frac{\text{Purity}}{100} \times \frac{\text{Weight of tablet}}{\text{Label claim}} \times 100$$

= 99.24%

The % purity[18] of Pazopanib in marketed pharmaceutical dosage form was found to be 99.24%.

Linearity

Linearity was performed by preparing a standard solution of Pazopanib at different concentration levels, i.e., 10–50 µg/mL. The absorbance was measured at 272 nm. Linearity[19] was proven by regression analysis by the least square method. The correlation coefficient and linearity results were presented in Table 4, and the linearity curve[20] was represented in Figure 3.

Table-4: Data for Linearity of Pazopanib

Concentration µg/ml	Average Peak Area
10	78683
20	146545
30	213584
40	279895
50	346568



Fig-3: Calibration Curve of Pazopanib

Linearity Plot:

The plot of Concentration (x) versus the Average Peak Area (y) data of Pazopanib is a straight line.

Y = mx + c

Slope (m) =6867

Intercept (c) = 5866

Correlation Coefficient (r) = 0.99

Validation Criteria: The response linearity is verified if the Correlation Coefficient[21] is 0.99 or greater.

Conclusion: Correlation Coefficient (r) is 0.99, and the intercept is 5866. These values meet the validation criteria.

Precision

Precision[22-25] was studied to find out intra-day and inter-day variation in the test methods of Pazopanib for 6 times on the same day and different day. The intra-day and inter-day precision[26] obtained was %RSD (<2.0) indicates that the proposed method is quite precise and reproducible, and results are shown in Table 5 and 6 & 7.

Table-5: Results of Method Precision for Pazopanib:

S. No.	Peak name	Retention time	Area (µV*sec)	Height (µV)	USP Plate Count	USP Tailing
1	Pazopanib	3.165	225645	20562	6125	1.36
2	Pazopanib	3.163	225847	20645	6129	1.36
3	Pazopanib	3.158	226542	20534	6135	1.35
4	Pazopanib	3.167	226598	20564	6189	1.36
5	Pazopanib	3.171	226584	20549	6138	1.35
6	Pazopanib	3.181	226859	20685	6179	1.37
Mean			226345.8			
Std. Dev			482.1068			
%RSD			0.212996			

Intermediate Precision:

Analyst 1:

Table-6: Results of Ruggedness for Analyst 1 for Pazopanib

S.No.	Peak Name	RT	Area (µV*sec)	Height (µV)	USP Plate Count	USP Tailing
1	Pazopanib	3.165	226534	20653	6235	1.35
2	Pazopanib	3.163	226542	20598	6198	1.36
3	Pazopanib	30158	225989	20653	6254	1.36
4	Pazopanib	3.167	226512	20548	6281	1.35
5	Pazopanib	3.171	226531	20653	6199	1.36
6	Pazopanib	3.171	225898	20658	6253	1.35
Mean			226334.3			
Std. Dev.			304.2622			
% RSD			0.13443			

Analyst 2:

Table-7: Results of Intermediate Precision Analyst 2 for Pazopanib

S.No.	Peak Name	RT	Area (µV*sec)	Height (µV)	USP Plate count	USP Tailing
1	Pazopanib	3.173	225487	20542	6253	1.35
2	Pazopanib	3.134	225484	20532	6098	1.36
3	Pazopanib	3.161	225364	20541	6254	1.35
4	Pazopanib	3.174	226513	20534	6235	1.36
5	Pazopanib	3.199	225487	20549	6199	1.36
6	Pazopanib	3.199	226532	20451	6235	1.35
Mean			225811.2			
Std. Dev.			553.0524			
% RSD			0.244918			

Accuracy

The accuracy[27] of the method was determined by the standard addition method. A known standard drug was added to the fixed amount of pre-analyzed drug sample solution. The standard addition method was performed

at three concentration levels in triplicate at 50%, 100%, and 150%. Percent recovery (Table 8) was calculated by comparing the peak area before and after adding the standard drug. Accuracy at different concentrations (50%, 100%, and 150%) was prepared and the % recovery was calculated.

Table-8: The Accuracy Results for Pazopanib

%Concentration (at specification Level)	Area	Amount Added (ppm)	Amount Found (ppm)	% Recovery	Mean Recovery
50%	109283.3	15	15.060	100.40%	100.42%
100%	212732	30	30.124	100.413%	
150%	316263.3	45	45.201	100.446%	

Limit of Detection

The detection limit[28] of an individual analytical procedure is the lowest amount of analyte in a sample which can be detected but not necessarily quantitated as an exact value.

$$\mathbf{LOD = 3.3 \times \sigma / s}$$

Where

σ = Standard deviation of the response

S = Slope of the calibration curve

Result:

= 0.597µg/ml

Limit of Quantitation

The quantitation limit[29] of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined.

$$\mathbf{LOQ = 10 \times \sigma / S}$$

Where

σ = Standard deviation of the response

S = Slope of the calibration curve

Result:

= 1.811µg/ml

Robustness

To demonstrate the method's robustness, prepared solution as per test method and injected at different variable conditions like using different conditions like flow rate and organic content in the mobile phase. The results for robustness[30] are represented in Table 9.

Table-9: Results for Robustness of Pazopanib

Parameter Used for Sample Analysis	Peak Area	Retention Time	Theoretical Plates	Tailing Factor
Actual Flow rate of 1.0 mL/min	225645	3.155	6125	1.36
Less Flow rate of 0.9 mL/min	236586	3.488	6452	1.38
More Flow rate of 1.1 mL/min	219865	2.877	6098	1.42
Less organic phase	235848	4.705	6126	1.43
More organic phase	241245	2.090	6324	1.39

SUMMARY AND CONCLUSION:

The analytical method was developed by studying different parameters. First of all, maximum absorbance was found to be at 272nm and the peak purity was excellent. Injection volume was selected to be 20µl which gave a good peak area. The column used for study was Symmetry ODS C_{18} (4.6mm x 250mm, 5µm) because it was giving good peak. Ambient temperature was found to be suitable for the nature of drug solution. The flow rate was fixed at 1.0ml/min because of good peak area and satisfactory retention time. Mobile phase is Acetonitrile and Methanol (80:20% v/v) was fixed due to good symmetrical peak. So this mobile phase was used for the proposed study. Run time was selected to be 8.0min because analyze gave peak around 3.123min and also to reduce the total run time. The percent recovery was found to be 98.0-102% was linear and precise over the same range. Both system and method precision were found to be accurate and well within range. The analytical method was found linearity over the range of 10-50µg/ml of the Pazopanib target concentration. The analytical passed both robustness and ruggedness tests. On both cases, relative standard deviation was well satisfactory. Hence the proposed RP-HPLC method proved to be simple, accurate and reproducible for the determination of Pazopanib in a reasonable run time. The method was validated showing satisfactory data for all the method validation parameters tested. The developed method can be conveniently used by quality control laboratories.

REFERENCES:

1. https://go.drugbank.com/drugs/DB06589
2. https://pubchem.ncbi.nlm.nih.gov/compound/Pazopanib

3. https://en.wikipedia.org/wiki/Pazopanib
4. Sharma BK. Instrumental methods of chemical analysis, Introduction to analytical chemistry, 23th ed .Goel publishing house Meerut, 2004, P12-23.
5. H.H. Willard, L.L. Merritt, J.A. Dean, F.A. Settle. Instrumental methods of analysis, 7th edition, CBS publishers and distributors, New Delhi. 1986, P.518-521, 580-610.
6. John Adamovies, Chromatographic analysis of pharmaceutical, Marcel Dekker Inc. New York, 2nd Ed, P.74, 5-15.
7. Gurdeep Chatwal, Sahm K. Anand. Instrumental methods of chemical analysis, 5th edition, Himalaya publishing house, New Delhi, 2002, P.1.1-1.8, 2.566-2.570
8. D. A. Skoog. J. Holler, T.A. Nieman. Principle of instrumental analysis, 5th edition, Saunders college publishing, 1998, P.778-787.
9. Skoog, Holler, Nieman. Principals of instrument al analysis 5th Ed, Harcourt Publisher's international company, 2001, P.543-554.
10. William Kemp. Organic spectroscopy, Palgrave, New York, 2005, P.7-10, 328-330
11. P.D. Sethi. HPLC: Quantitative analysis pharmaceutical formulations, CBS publishers and distributors, New Delhi (India), 2001, P.3-137.
12. Michael E, Schartz IS, Krull. Analytical method development and validation. 2004, P. 25-46.
13. R. Snyder, J. Kirkland, L. Glajch. Practical HPLC method development, 2nd Ed, a Wiley international publication, 1997, P.235, 266-268, 351-353.653-600.686-695.
14. Basic education in analytical chemistry. Analytical science, 2001:17(1).
15. Method validation guidelines international conference on harmonization; GENEVA; 1996
16. Berry RI, Nash AR. Pharmaceutical process validation, Analytical method validation, Marcel Dekker Inc. New work, 1993; 57:411-28
17. Anthony C Moffat, M David Osselton, Brian Widdop. Clarke's analysis of drugs and poisons, Pharmaceutical press, London, 2004, P.1109-1110, 1601-1602.
18. Klaus Florey, Analysis profile of drugs substances, Academic press, New York, 2005, P.406-435.
19. P.N. Arora, P.K. Malhan. Biostatistics, Himalaya Publishers house, India, P.113, 139-140,154.
20. L. R. Snyder, J.J. Kirkland, and J. W. Dolan, Introduction to Modern Liquid Chromatography, John Wiley & Sons, New York, 2009.
21. M.W. Dong, Modern HPLC for practicing scientists. Wiley, 2006.
22. L. R. Snyder, J.J. Kirkland, and J. L. Glajch, Practical HPLC Method Development, John Wiley & Sons, New York, 1997.
23. S. Ahuja and H. T. Rasmussen (Ed), HPLC Method Development for Pharmaceuticals, Academic Press, 2007.
24. S. Ahuja and M.W. Dong (Ed), Handbook of Pharmaceutical Analysis by HPLC, Elsevier/Academic Press, 2005.
25. Y. V. Kazakevich and R. LoBrutto (ed.), HPLC for Pharmaceutical Scientists, Wiley, 2007.
26. U. D. Neue, HPLC Columns: Theory, Technology, and Practice, Wiley-VCH, New York, 1997.
27. M. C. McMaster, HPLC, a practical user's guide, Wiley, 2007.
28. Doserge, Wilson and Gisvold's text book of organic medicinal and pharmaceutical chemistry, 8th Ed, Lippincott Company, 1982, P.183-197.
29. Snyder, Lloyd R.; Dolan, John W. (2006). High-Performance Gradient Elution: The Practical Application of the Linear-Solvent-Strength Model. Wiley Interscience.
30. Giddings, J. Calvin (1965) Dynamics of Chromatography, Part I. Principles and Theory. Marcel Dekker, Inc., New York. p. 281.
31. K., Robards (1994). Principles and practice of modern chromatographic methods. Haddad, P. R., Jackson, P. E. Amsterdam: Elsevier/Academic Press.
32. ICH Guidance. Validation of analytical methods - definition and terminology. Q2A. Geneva: International Conference on Harmonization. Nov 2005.
33. ICH Guidance, Validation of analytical procedures - methodology. Q2B. Geneva: International Conference on Harmonization. Nov 2005.
34. Kiran Kumar Buralla1, Varadarajan Parthasarathy2,*, Validated RP-HPLC Method Development of Pazopanib in Bulk and its Pharmaceutical Dosage Form, Pharm Methods, 2020; 11(1):21-24.
35. P. Ravi Sankar, K. Sai Sneha Latha, A. Bhavani Sailu, SK. Taheera, B. Madhuri, Development and Validation of RP-HPLC Method for the Determination of Pazopanib Hydrochloride (A Tyrosine Kinase Inhibitor) in Pharmaceutical Dosage Form, Research J. Pharm. and Tech 2021; 14(3):1549-1554. Doi: 10.5958/0974-360X.2021.00273.0.